Answers are grounded in this paper and cite their sources.
Importance There is a high level of interest in cannabidiol (CBD) as treatment for severe behavioral problems in children with intellectual disabilities. Given the lack of evidence, clinical trials are needed to inform practice. Objective To investigate the efficacy of CBD to reduce severe behavioral problems in children and adolescents with intellectual disability. Design, Setting, and Participants This parallel design, double-blind placebo-controlled randomized clinical trial was conducted between May 11, 2021, and May 8, 2025. Participants were children and adolescents aged 6 to 18 years with an intellectual disability and severe behavioral problems from 3 children’s hospitals in Australia: The Royal Children’s Hospital in Melbourne, Monash Children’s Hospital in Melbourne, and The Children’s Hospital Westmead in Sydney. Intervention Participants were randomly assigned 1:1 to receive CBD isolate in oil (10 mg/kg/d) or placebo orally for 8 weeks, with a 4-week follow-up period. Main Outcome and Measure The primary outcome was parent-reported score on the Aberrant Behavior Checklist, Irritability (ABC-I) subscale assessed at the end of the 8-week maintenance phase. Results Of 131 participants randomized after exclusion of 1 participant randomized in error, 65 were in the CBD group and 66 were in the placebo group. Overall, mean (SD) age was 11.2 (3.1) years, and 98 participants (74.8%) were male. A total of 110 participants (84.0%) had comorbid autism. Primary outcome data were available for 61 participants in the CBD group and 63 in the placebo group. Mean (SD) ABC-I subscale scores at baseline were 32.2 (7.3) and 30.0 (6.3) in the CBD and placebo groups, respectively. Intention-to-treat analysis showed similar mean (SD) ABC-I subscale scores at the end of treatment: 21.7 (11.0) in the CBD group and 19.2 (10.7) in the placebo group (mean difference, 2.4; 95% CI, −1.5 to 6.3). A similar proportion of participants experienced at least 1 adverse event in the CBD group (41 [63.1%]) and the placebo group (40 [60.6%]). Conclusions and Relevance In this randomized clinical trial, CBD was not effective in treating severe behavioral problems in youths with intellectual disability. The results suggest that CBD should not be used to treat severe behavioral problems in this population. Trial Registration ClinicalTrials.gov Identifier: NCT04821856
No takes yet. Share an insight, caveat, or question.
Efron et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: